25 XP   0   0   10

Hikma Pharmaceuticals PLC
Buy, Hold or Sell?

Let's analyse Hikma Pharmaceuticals PLC together

PenkeI guess you are interested in Hikma Pharmaceuticals PLC. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

I'm going to help you getting a better view of Hikma Pharmaceuticals PLC. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

You can find me behind Let's Analyse Together in the top-right of each section.

Get notifications about Hikma Pharmaceuticals PLC

I send you an email if I find something interesting about Hikma Pharmaceuticals PLC.

Quick analysis of Hikma Pharmaceuticals PLC (30 sec.)










What can you expect buying and holding a share of Hikma Pharmaceuticals PLC? (30 sec.)

How much money do you get?

How much money do you get?
€619.44
When do you have the money?
1 year
How often do you get paid?
100.0%

What is your share worth?

Current worth
€16,043.36
Expected worth in 1 year
€19,539.34
How sure are you?
89.7%

+ What do you gain per year?

Total Gains per Share
€4,077.82
Return On Investment
2,755.3%

For what price can you sell your share?

Current Price per Share
€148.00
Expected price per share
€25.91 - €173.00
How sure are you?
50%

1. Valuation of Hikma Pharmaceuticals PLC (5 min.)




Live pricePrice per Share (EOD)

€148.00

Intrinsic Value Per Share

€10,563.88 - €12,251.03

Total Value Per Share

€26,607.25 - €28,294.39

2. Growth of Hikma Pharmaceuticals PLC (5 min.)




Is Hikma Pharmaceuticals PLC growing?

Current yearPrevious yearGrowGrow %
How rich?$755b$565.5b$139.6b19.8%

How much money is Hikma Pharmaceuticals PLC making?

Current yearPrevious yearGrowGrow %
Making money$26.2b$25.3b$881.2m3.4%
Net Profit Margin16.1%15.2%--

How much money comes from the company's main activities?

3. Financial Health of Hikma Pharmaceuticals PLC (5 min.)




4. Comparing to competitors in the Conglomerates industry (5 min.)




  Industry Rankings (Conglomerates)  


Richest
#1 / 247

Most Revenue
#2 / 247

Most Profit
#1 / 247

What can you expect buying and holding a share of Hikma Pharmaceuticals PLC? (5 min.)

Welcome investor! Hikma Pharmaceuticals PLC's management wants to use your money to grow the business. In return you get a share of Hikma Pharmaceuticals PLC.

What can you expect buying and holding a share of Hikma Pharmaceuticals PLC?

First you should know what it really means to hold a share of Hikma Pharmaceuticals PLC. And how you can make/lose money.

Speculation

The Price per Share of Hikma Pharmaceuticals PLC is €148.00. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Hikma Pharmaceuticals PLC.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Hikma Pharmaceuticals PLC, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is €16,043.36. Based on the TTM, the Book Value Change Per Share is €873.99 per quarter. Based on the YOY, the Book Value Change Per Share is €515.69 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is €145.46 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Hikma Pharmaceuticals PLC.

How much money are you going to get?

 MRQTTMYOY5Y10Y
 % of Price per Share% of Price per Share% of Price per Share% of Price per Share% of Price per Share
Usd Eps290.84196.5%637.45430.7%566.98383.1%397.90268.9%306.32207.0%
Usd Book Value Change Per Share493.32333.3%930.45628.7%549.01371.0%848.72573.5%588.96397.9%
Usd Dividend Per Share164.02110.8%154.86104.6%137.8793.2%112.1175.7%87.5759.2%
Usd Total Gains Per Share657.34444.1%1,085.31733.3%686.87464.1%960.83649.2%676.53457.1%
Usd Price Per Share158.09-146.36-119.58-165.50-153.92-
Price to Earnings Ratio0.14-0.07-0.08-1.23-2.31-
Price-to-Total Gains Ratio0.24-0.15-0.31-2.91-3.34-
Price to Book Ratio0.01-0.01-0.01-0.25-0.43-
Price-to-Total Gains Ratio0.24-0.15-0.31-2.91-3.34-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share157.5608
Number of shares6
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share154.86112.11
Usd Book Value Change Per Share930.45848.72
Usd Total Gains Per Share1,085.31960.83
Gains per Quarter (6 shares)6,511.875,764.98
Gains per Year (6 shares)26,047.4923,059.94
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
13717223312603726912036923050
27433446625208453814073946110
311150669937813180726110869170
41486689324104178107628147792230
51858311165413022513453101847115290
62230013398515627216144122216138350
72601615631618231918834142585161410
82973317864720836621525162955184470
93344920097823441324216183324207530
103716622330926046026906203693230590

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share4.00.00.0100.0%12.00.00.0100.0%20.00.00.0100.0%29.00.00.0100.0%29.00.00.0100.0%
Book Value Change Per Share4.00.00.0100.0%12.00.00.0100.0%19.01.00.095.0%26.03.00.089.7%26.03.00.089.7%
Dividend per Share4.00.00.0100.0%12.00.00.0100.0%20.00.00.0100.0%29.00.00.0100.0%29.00.00.0100.0%
Total Gains per Share4.00.00.0100.0%12.00.00.0100.0%19.01.00.095.0%26.03.00.089.7%26.03.00.089.7%

Fundamentals of Hikma Pharmaceuticals PLC

About Hikma Pharmaceuticals PLC

Hikari Tsushin, Inc., a holding company, engages in the sale of communication-related products in Japan. The company provides communication line services, water delivery, electricity, insurance, industry-specific IT solutions, payment solutions, mobile phones, and office automation products to individual and corporate customers. Hikari Tsushin, Inc. was incorporated in 1952 and is headquartered in Tokyo, Japan.

Fundamental data was last updated by Penke on 2024-04-18 07:58:05.

Financial Health

Profitability Details
 Compared to previous yearCompared to industry
The company is making a huge profit.
Using its assets, the company is less efficient in making profit.
Using its investors money, the company is inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
The company is operating less efficient.
The company is inefficient in keeping operating costs low.
Liquidity Details
 Compared to previous yearCompared to industry
The company is able to pay all its short-term debts.
The company is just not able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is able to pay all its debts by selling its assets.
The company is just able to pay all its debts with equity.

Valuation

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is cheap.
Based on the earnings, the company is cheap.
Based on how much money comes from the company's main activities, the company is cheap.

1.1. Profitability of Hikma Pharmaceuticals PLC.

1.1. Profitability
1.1.1. Net Profit Margin

Measures how much net profit Hikma Pharmaceuticals PLC earns for each €1 of revenue.

  • Above 10% is considered healthy but always compare Hikma Pharmaceuticals PLC to the Conglomerates industry mean.
  • A Net Profit Margin of 8.0% means that €0.08 for each €1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Hikma Pharmaceuticals PLC:

  • The MRQ is 8.0%. The company is making a profit. +1
  • The TTM is 16.1%. The company is making a huge profit. +2
Trends
Current periodCompared to+/- 
MRQ8.0%TTM16.1%-8.0%
TTM16.1%YOY15.2%+0.9%
TTM16.1%5Y12.9%+3.2%
5Y12.9%10Y11.8%+1.0%
Compared to industry (Conglomerates)
PeriodCompanyIndustry (mean)+/- 
MRQ8.0%3.6%+4.4%
TTM16.1%3.6%+12.5%
YOY15.2%4.0%+11.2%
5Y12.9%3.3%+9.6%
10Y11.8%3.8%+8.0%
1.1.2. Return on Assets

Shows how efficient Hikma Pharmaceuticals PLC is using its assets to generate profit.

  • Above 5% is considered healthy but always compare Hikma Pharmaceuticals PLC to the Conglomerates industry mean.
  • 0.6% Return on Assets means that Hikma Pharmaceuticals PLC generated €0.01 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Hikma Pharmaceuticals PLC:

  • The MRQ is 0.6%. Using its assets, the company is inefficient in making profit. -1
  • The TTM is 1.4%. Using its assets, the company is less efficient in making profit.
Trends
Current periodCompared to+/- 
MRQ0.6%TTM1.4%-0.7%
TTM1.4%YOY1.6%-0.2%
TTM1.4%5Y1.4%-0.1%
5Y1.4%10Y1.5%-0.1%
Compared to industry (Conglomerates)
PeriodCompanyIndustry (mean)+/- 
MRQ0.6%0.8%-0.2%
TTM1.4%0.9%+0.5%
YOY1.6%1.2%+0.4%
5Y1.4%0.8%+0.6%
10Y1.5%0.9%+0.6%
1.1.3. Return on Equity

Shows how efficient Hikma Pharmaceuticals PLC is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare Hikma Pharmaceuticals PLC to the Conglomerates industry mean.
  • 1.8% Return on Equity means Hikma Pharmaceuticals PLC generated €0.02 for each €1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Hikma Pharmaceuticals PLC:

  • The MRQ is 1.8%. Using its investors money, the company is inefficient in making profit. -1
  • The TTM is 3.9%. Using its investors money, the company is inefficient in making profit. -1
Trends
Current periodCompared to+/- 
MRQ1.8%TTM3.9%-2.2%
TTM3.9%YOY4.8%-0.9%
TTM3.9%5Y4.4%-0.5%
5Y4.4%10Y4.6%-0.2%
Compared to industry (Conglomerates)
PeriodCompanyIndustry (mean)+/- 
MRQ1.8%2.1%-0.3%
TTM3.9%2.5%+1.4%
YOY4.8%3.7%+1.1%
5Y4.4%2.4%+2.0%
10Y4.6%2.7%+1.9%

1.2. Operating Efficiency of Hikma Pharmaceuticals PLC.

1.2. Operating Efficiency
1.2.1. Operating Margin

Measures how efficient Hikma Pharmaceuticals PLC is operating .

  • Measures how much profit Hikma Pharmaceuticals PLC makes for each €1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare Hikma Pharmaceuticals PLC to the Conglomerates industry mean.
  • An Operating Margin of 0.0% means the company generated €0.00  for each €1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Hikma Pharmaceuticals PLC:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM7.5%-7.5%
TTM7.5%YOY8.9%-1.4%
TTM7.5%5Y13.1%-5.6%
5Y13.1%10Y12.6%+0.5%
Compared to industry (Conglomerates)
PeriodCompanyIndustry (mean)+/- 
MRQ-7.9%-7.9%
TTM7.5%5.0%+2.5%
YOY8.9%6.4%+2.5%
5Y13.1%5.4%+7.7%
10Y12.6%5.7%+6.9%
1.2.2. Operating Ratio

Measures how efficient Hikma Pharmaceuticals PLC is keeping operating costs low.

  • Below 1 is considered healthy (always compare to Conglomerates industry mean).
  • An Operation Ratio of 1.32 means that the operating costs are €1.32 for each €1 in net sales.

Let's take a look of the Operating Ratio trends of Hikma Pharmaceuticals PLC:

  • The MRQ is 1.320. The company is inefficient in keeping operating costs low. -1
  • The TTM is 1.328. The company is inefficient in keeping operating costs low. -1
Trends
Current periodCompared to+/- 
MRQ1.320TTM1.328-0.008
TTM1.328YOY1.445-0.117
TTM1.3285Y1.333-0.005
5Y1.33310Y1.308+0.025
Compared to industry (Conglomerates)
PeriodCompanyIndustry (mean)+/- 
MRQ1.3201.518-0.198
TTM1.3281.493-0.165
YOY1.4451.393+0.052
5Y1.3331.349-0.016
10Y1.3081.267+0.041

1.3. Liquidity of Hikma Pharmaceuticals PLC.

1.3. Liquidity
1.3.1. Current Ratio

Measures if Hikma Pharmaceuticals PLC is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to Conglomerates industry mean).
  • A Current Ratio of 1.82 means the company has €1.82 in assets for each €1 in short-term debts.

Let's take a look of the Current Ratio trends of Hikma Pharmaceuticals PLC:

  • The MRQ is 1.817. The company is able to pay all its short-term debts. +1
  • The TTM is 1.861. The company is able to pay all its short-term debts. +1
Trends
Current periodCompared to+/- 
MRQ1.817TTM1.861-0.044
TTM1.861YOY1.779+0.082
TTM1.8615Y1.771+0.090
5Y1.77110Y1.848-0.077
Compared to industry (Conglomerates)
PeriodCompanyIndustry (mean)+/- 
MRQ1.8171.453+0.364
TTM1.8611.464+0.397
YOY1.7791.464+0.315
5Y1.7711.561+0.210
10Y1.8481.512+0.336
1.3.2. Quick Ratio

Measures if Hikma Pharmaceuticals PLC is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare Hikma Pharmaceuticals PLC to the Conglomerates industry mean.
  • A Quick Ratio of 0.71 means the company can pay off €0.71 for each €1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Hikma Pharmaceuticals PLC:

  • The MRQ is 0.713. The company is just not able to pay all its short-term debts with the most liquid assets. -1
  • The TTM is 0.755. The company is just not able to pay all its short-term debts with the most liquid assets. -1
Trends
Current periodCompared to+/- 
MRQ0.713TTM0.755-0.042
TTM0.755YOY0.752+0.003
TTM0.7555Y0.730+0.026
5Y0.73010Y0.788-0.059
Compared to industry (Conglomerates)
PeriodCompanyIndustry (mean)+/- 
MRQ0.7130.703+0.010
TTM0.7550.724+0.031
YOY0.7520.800-0.048
5Y0.7300.857-0.127
10Y0.7880.832-0.044

1.4. Solvency of Hikma Pharmaceuticals PLC.

1.3. Liquidity
1.4.1. Debt to Asset Ratio

Measures how much % of Hikma Pharmaceuticals PLC assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare Hikma Pharmaceuticals PLC to Conglomerates industry mean.
  • A Debt to Asset Ratio of 0.63 means that Hikma Pharmaceuticals PLC assets are financed with 62.6% credit (debt) and the remaining percentage (100% - 62.6%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of Hikma Pharmaceuticals PLC:

  • The MRQ is 0.626. The company is able to pay all its debts by selling its assets. +1
  • The TTM is 0.632. The company is able to pay all its debts by selling its assets. +1
Trends
Current periodCompared to+/- 
MRQ0.626TTM0.632-0.006
TTM0.632YOY0.655-0.023
TTM0.6325Y0.649-0.017
5Y0.64910Y0.642+0.007
Compared to industry (Conglomerates)
PeriodCompanyIndustry (mean)+/- 
MRQ0.6260.561+0.065
TTM0.6320.561+0.071
YOY0.6550.564+0.091
5Y0.6490.568+0.081
10Y0.6420.558+0.084
1.4.2. Debt to Equity Ratio

Measures if Hikma Pharmaceuticals PLC is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare Hikma Pharmaceuticals PLC to the Conglomerates industry mean.
  • A Debt to Equity ratio of 173.9% means that company has €1.74 debt for each €1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Hikma Pharmaceuticals PLC:

  • The MRQ is 1.739. The company is just able to pay all its debts with equity.
  • The TTM is 1.791. The company is just able to pay all its debts with equity.
Trends
Current periodCompared to+/- 
MRQ1.739TTM1.791-0.052
TTM1.791YOY2.006-0.215
TTM1.7915Y1.989-0.198
5Y1.98910Y1.933+0.057
Compared to industry (Conglomerates)
PeriodCompanyIndustry (mean)+/- 
MRQ1.7391.354+0.385
TTM1.7911.342+0.449
YOY2.0061.384+0.622
5Y1.9891.587+0.402
10Y1.9331.509+0.424

2. Market Valuation of Hikma Pharmaceuticals PLC

2.1. Earnings Per Share
2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every €1 in earnings Hikma Pharmaceuticals PLC generates.

  • Above 15 is considered overpriced but always compare Hikma Pharmaceuticals PLC to the Conglomerates industry mean.
  • A PE ratio of 0.14 means the investor is paying €0.14 for every €1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Hikma Pharmaceuticals PLC:

  • The EOD is 0.135. Based on the earnings, the company is cheap. +2
  • The MRQ is 0.136. Based on the earnings, the company is cheap. +2
  • The TTM is 0.070. Based on the earnings, the company is cheap. +2
Trends
Current periodCompared to+/- 
EOD0.135MRQ0.1360.000
MRQ0.136TTM0.070+0.066
TTM0.070YOY0.084-0.015
TTM0.0705Y1.233-1.164
5Y1.23310Y2.308-1.075
Compared to industry (Conglomerates)
PeriodCompanyIndustry (mean)+/- 
EOD0.1357.621-7.486
MRQ0.1367.538-7.402
TTM0.0707.640-7.570
YOY0.0847.097-7.013
5Y1.2339.028-7.795
10Y2.30813.828-11.520
2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of Hikma Pharmaceuticals PLC:

  • The EOD is 0.107. Based on how much money comes from the company's main activities, the company is cheap. +2
  • The MRQ is 0.107. Based on how much money comes from the company's main activities, the company is cheap. +2
  • The TTM is 0.062. Based on how much money comes from the company's main activities, the company is cheap. +2
Trends
Current periodCompared to+/- 
EOD0.107MRQ0.1070.000
MRQ0.107TTM0.062+0.045
TTM0.062YOY-1.567+1.629
TTM0.0625Y-0.224+0.286
5Y-0.22410Y-0.155-0.070
Compared to industry (Conglomerates)
PeriodCompanyIndustry (mean)+/- 
EOD0.1072.073-1.966
MRQ0.1072.189-2.082
TTM0.0621.300-1.238
YOY-1.5670.597-2.164
5Y-0.2240.724-0.948
10Y-0.1550.743-0.898
2. Book Value per Share
2.3. Price to Book Ratio

Measures if the stock price of Hikma Pharmaceuticals PLC is to cheap or to expensive compared to its book value.

  • At or below 1 is considered healthy (always compare to Conglomerates industry mean).
  • A PB ratio of 0.01 means the investor is paying €0.01 for each €1 in book value.

Let's take a look of the Price to Book Ratio trends of Hikma Pharmaceuticals PLC:

  • The EOD is 0.009. Based on the equity, the company is cheap. +2
  • The MRQ is 0.009. Based on the equity, the company is cheap. +2
  • The TTM is 0.009. Based on the equity, the company is cheap. +2
Trends
Current periodCompared to+/- 
EOD0.009MRQ0.0090.000
MRQ0.009TTM0.009+0.000
TTM0.009YOY0.0090.000
TTM0.0095Y0.252-0.242
5Y0.25210Y0.427-0.175
Compared to industry (Conglomerates)
PeriodCompanyIndustry (mean)+/- 
EOD0.0090.953-0.944
MRQ0.0090.971-0.962
TTM0.0090.976-0.967
YOY0.0091.089-1.080
5Y0.2521.115-0.863
10Y0.4271.327-0.900
2. Total Gains per Share

3. Summary

3.1. Key Performance Indicators

The key performance indicators of Hikma Pharmaceuticals PLC compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-5 Year+/-10 Year+/-
Book Value Change Per Share--463.384873.993-47%515.695-10%797.221-42%553.219-16%
Book Value Per Share--16043.36514906.912+8%11867.801+35%9308.791+72%7058.694+127%
Current Ratio--1.8171.861-2%1.779+2%1.771+3%1.848-2%
Debt To Asset Ratio--0.6260.632-1%0.655-4%0.649-3%0.642-2%
Debt To Equity Ratio--1.7391.791-3%2.006-13%1.989-13%1.933-10%
Dividend Per Share--154.068145.462+6%129.500+19%105.306+46%82.260+87%
Eps--273.187598.765-54%532.578-49%373.758-27%287.734-5%
Free Cash Flow Per Share--346.681620.779-44%105.624+228%286.897+21%286.897+21%
Free Cash Flow To Equity Per Share--346.681846.204-59%499.669-31%640.584-46%640.584-46%
Gross Profit Margin--1.0001.0000%1.0000%1.0000%1.0000%
Intrinsic Value_10Y_max--12251.027--------
Intrinsic Value_10Y_min--10563.885--------
Intrinsic Value_1Y_max--1107.897--------
Intrinsic Value_1Y_min--1088.154--------
Intrinsic Value_3Y_max--3420.041--------
Intrinsic Value_3Y_min--3263.211--------
Intrinsic Value_5Y_max--5842.229--------
Intrinsic Value_5Y_min--5414.751--------
Market Cap6533386000.0000%6564850281.0006108960935.100+7%5027328719.425+31%76191167223.785-91%115367727350.110-94%
Net Profit Margin--0.0800.161-50%0.152-47%0.129-38%0.118-32%
Operating Margin---0.075-100%0.089-100%0.131-100%0.126-100%
Operating Ratio--1.3201.328-1%1.445-9%1.333-1%1.308+1%
Pb Ratio0.0090%0.0090.009+0%0.009-2%0.252-96%0.427-98%
Pe Ratio0.1350%0.1360.070+95%0.084+61%1.233-89%2.308-94%
Price Per Share148.0000%148.500137.475+8%112.325+32%155.454-4%144.580+3%
Price To Free Cash Flow Ratio0.1070%0.1070.062+72%-1.567+1563%-0.224+309%-0.155+244%
Price To Total Gains Ratio0.2400%0.2410.149+62%0.306-21%2.914-92%3.338-93%
Quick Ratio--0.7130.755-6%0.752-5%0.730-2%0.788-10%
Return On Assets--0.0060.014-54%0.016-59%0.014-56%0.015-59%
Return On Equity--0.0180.039-55%0.048-63%0.044-60%0.046-62%
Total Gains Per Share--617.4521019.455-39%645.195-4%902.528-32%635.479-3%
Usd Book Value--755057968600.000705197161450.000+7%565516052300.000+34%492731266580.000+53%414509021675.862+82%
Usd Book Value Change Per Share--493.319930.453-47%549.009-10%848.722-42%588.957-16%
Usd Book Value Per Share--17079.76615869.899+8%12634.461+35%9910.139+72%7514.686+127%
Usd Dividend Per Share--164.021154.859+6%137.866+19%112.109+46%87.574+87%
Usd Eps--290.835637.445-54%566.982-49%397.903-27%306.322-5%
Usd Free Cash Flow--16316059600.00029400259750.000-45%5090118750.000+221%11002641000.000+48%7588028275.862+115%
Usd Free Cash Flow Per Share--369.077660.881-44%112.447+228%305.430+21%305.430+21%
Usd Free Cash Flow To Equity Per Share--369.077900.869-59%531.948-31%681.966-46%681.966-46%
Usd Market Cap6955442735.6000%6988939609.1536503599811.507+7%5352094154.700+31%81113116626.442-91%122820482536.927-94%
Usd Price Per Share157.5610%158.093146.356+8%119.581+32%165.496-4%153.920+3%
Usd Profit--12857174200.00026250108350.000-51%25368885700.000-49%19920262900.000-35%17249053013.793-25%
Usd Revenue--159912501400.000165055051700.000-3%168045513100.000-5%153888089690.000+4%142726369917.241+12%
Usd Total Gains Per Share--657.3401085.312-39%686.874-4%960.831-32%676.531-3%
 EOD+4 -4MRQTTM+12 -23YOY+16 -195Y+16 -1910Y+14 -21

3.2. Fundamental Score

Let's check the fundamental score of Hikma Pharmaceuticals PLC based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-150.135
Price to Book Ratio (EOD)Between0-10.009
Net Profit Margin (MRQ)Greater than00.080
Operating Margin (MRQ)Greater than00.000
Quick Ratio (MRQ)Greater than10.713
Current Ratio (MRQ)Greater than11.817
Debt to Asset Ratio (MRQ)Less than10.626
Debt to Equity Ratio (MRQ)Less than11.739
Return on Equity (MRQ)Greater than0.150.018
Return on Assets (MRQ)Greater than0.050.006
Total5/10 (50.0%)

3.3. Technical Score

Let's check the technical score of Hikma Pharmaceuticals PLC based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
OpenGreater thanClose148.000
Total0/1 (0.0%)



Latest Balance Sheet

Balance Sheet of 2023-12-31. Currency in EUR. All numbers in thousands.

Summary
Total Assets1,896,561,000
Total Liabilities1,187,320,000
Total Stockholder Equity682,747,000
 As reported
Total Liabilities 1,187,320,000
Total Stockholder Equity+ 682,747,000
Total Assets = 1,896,561,000

Assets

Total Assets1,896,561,000
Total Current Assets804,898,000
Long-term Assets1,091,662,000
Total Current Assets
Cash And Cash Equivalents 454,919,000
Short-term Investments 53,496,000
Net Receivables 262,272,000
Inventory 2,672,000
Other Current Assets 10,023,000
Total Current Assets  (as reported)804,898,000
Total Current Assets  (calculated)783,382,000
+/- 21,516,000
Long-term Assets
Property Plant Equipment 39,728,000
Goodwill 19,434,000
Intangible Assets 6,336,000
Long-term Assets Other 95,000
Long-term Assets  (as reported)1,091,662,000
Long-term Assets  (calculated)65,593,000
+/- 1,026,069,000

Liabilities & Shareholders' Equity

Total Current Liabilities442,969,000
Long-term Liabilities744,351,000
Total Stockholder Equity682,747,000
Total Current Liabilities
Short Long Term Debt 179,241,000
Accounts payable 212,376,000
Other Current Liabilities 17,885,000
Total Current Liabilities  (as reported)442,969,000
Total Current Liabilities  (calculated)409,502,000
+/- 33,467,000
Long-term Liabilities
Long term Debt 623,678,000
Long-term Liabilities Other 22,981,000
Long-term Liabilities  (as reported)744,351,000
Long-term Liabilities  (calculated)646,659,000
+/- 97,692,000
Total Stockholder Equity
Retained Earnings 650,036,000
Total Stockholder Equity (as reported)682,747,000
Total Stockholder Equity (calculated)650,036,000
+/- 32,711,000
Other
Capital Stock54,259,000
Common Stock Shares Outstanding 44,208
Net Debt 348,000,000
Net Invested Capital 1,485,666,000
Net Working Capital 361,929,000
Property Plant and Equipment Gross 39,728,000



Balance Sheet

Currency in EUR. All numbers in thousands.

 Trend2023-12-312023-09-302023-06-302023-03-312022-12-312022-09-302022-06-302022-03-312021-12-312021-09-302021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-302017-03-312016-12-31
> Total Assets 
448,547,000
511,487,000
502,697,000
579,357,000
617,014,000
681,466,000
678,325,000
754,345,000
731,321,000
804,207,000
815,398,000
916,502,000
1,000,422,000
972,075,000
972,511,000
1,053,792,000
1,109,544,000
1,256,844,000
1,304,920,000
1,311,522,000
1,383,331,000
1,450,453,000
1,473,329,000
1,605,982,000
1,621,115,000
1,691,949,000
1,773,841,000
1,823,058,000
1,896,561,000
1,896,561,0001,823,058,0001,773,841,0001,691,949,0001,621,115,0001,605,982,0001,473,329,0001,450,453,0001,383,331,0001,311,522,0001,304,920,0001,256,844,0001,109,544,0001,053,792,000972,511,000972,075,0001,000,422,000916,502,000815,398,000804,207,000731,321,000754,345,000678,325,000681,466,000617,014,000579,357,000502,697,000511,487,000448,547,000
   > Total Current Assets 
243,945,000
312,203,000
289,844,000
344,398,000
346,985,000
388,676,000
345,199,000
385,201,000
355,735,000
388,238,000
370,584,000
440,732,000
459,020,000
494,449,000
452,621,000
485,836,000
493,567,000
578,588,000
585,858,000
535,526,000
577,741,000
628,385,000
636,696,000
718,581,000
692,592,000
727,839,000
757,334,000
776,255,000
804,898,000
804,898,000776,255,000757,334,000727,839,000692,592,000718,581,000636,696,000628,385,000577,741,000535,526,000585,858,000578,588,000493,567,000485,836,000452,621,000494,449,000459,020,000440,732,000370,584,000388,238,000355,735,000385,201,000345,199,000388,676,000346,985,000344,398,000289,844,000312,203,000243,945,000
       Cash And Cash Equivalents 
85,291,000
119,323,000
129,441,000
169,546,000
148,975,000
185,813,000
172,984,000
199,406,000
165,001,000
186,325,000
186,750,000
230,368,000
261,115,000
272,187,000
251,239,000
284,285,000
277,046,000
324,530,000
351,573,000
297,501,000
321,184,000
338,249,000
342,807,000
398,963,000
367,376,000
389,366,000
437,790,000
443,372,000
454,919,000
454,919,000443,372,000437,790,000389,366,000367,376,000398,963,000342,807,000338,249,000321,184,000297,501,000351,573,000324,530,000277,046,000284,285,000251,239,000272,187,000261,115,000230,368,000186,750,000186,325,000165,001,000199,406,000172,984,000185,813,000148,975,000169,546,000129,441,000119,323,00085,291,000
       Short-term Investments 
0
0
0
0
0
0
0
0
0
3,325,000
3,865,000
3,949,000
3,351,000
13,500,000
7,315,000
6,281,000
4,605,000
4,554,000
4,791,000
4,429,000
5,024,000
10,904,000
19,319,000
19,299,000
20,446,000
20,207,000
30,599,000
46,119,000
53,496,000
53,496,00046,119,00030,599,00020,207,00020,446,00019,299,00019,319,00010,904,0005,024,0004,429,0004,791,0004,554,0004,605,0006,281,0007,315,00013,500,0003,351,0003,949,0003,865,0003,325,000000000000
       Net Receivables 
129,295,000
151,365,000
131,196,000
145,098,000
158,870,000
167,260,000
152,092,000
166,209,000
167,103,000
178,186,000
162,774,000
181,508,000
177,495,000
193,011,000
173,201,000
182,180,000
197,119,000
228,454,000
206,228,000
215,073,000
230,104,000
265,544,000
241,282,000
276,057,000
278,386,000
301,269,000
257,904,000
272,556,000
262,272,000
262,272,000272,556,000257,904,000301,269,000278,386,000276,057,000241,282,000265,544,000230,104,000215,073,000206,228,000228,454,000197,119,000182,180,000173,201,000193,011,000177,495,000181,508,000162,774,000178,186,000167,103,000166,209,000152,092,000167,260,000158,870,000145,098,000131,196,000151,365,000129,295,000
       Inventory 
16,176,000
15,180,000
11,502,000
11,044,000
16,943,000
11,882,000
3,479,000
3,188,000
3,559,000
2,420,000
2,030,000
2,237,000
2,100,000
2,168,000
1,286,000
1,083,000
1,821,000
1,760,000
1,655,000
1,758,000
1,853,000
1,771,000
1,657,000
1,482,000
1,646,000
2,927,000
2,685,000
2,527,000
2,672,000
2,672,0002,527,0002,685,0002,927,0001,646,0001,482,0001,657,0001,771,0001,853,0001,758,0001,655,0001,760,0001,821,0001,083,0001,286,0002,168,0002,100,0002,237,0002,030,0002,420,0003,559,0003,188,0003,479,00011,882,00016,943,00011,044,00011,502,00015,180,00016,176,000
       Other Current Assets 
13,183,000
23,337,000
17,705,000
18,710,000
22,197,000
20,335,000
16,644,000
16,398,000
20,072,000
15,556,000
15,165,000
11,140,000
14,959,000
10,258,000
19,580,000
12,007,000
12,976,000
14,632,000
21,611,000
16,765,000
19,576,000
5,596,000
31,631,000
22,780,000
24,738,000
12,522,000
28,356,000
9,184,000
10,023,000
10,023,0009,184,00028,356,00012,522,00024,738,00022,780,00031,631,0005,596,00019,576,00016,765,00021,611,00014,632,00012,976,00012,007,00019,580,00010,258,00014,959,00011,140,00015,165,00015,556,00020,072,00016,398,00016,644,00020,335,00022,197,00018,710,00017,705,00023,337,00013,183,000
   > Long-term Assets 
0
0
0
0
0
0
0
0
0
415,969,000
444,814,000
475,770,000
541,401,000
477,625,000
519,889,000
567,956,000
615,976,000
678,256,000
719,061,000
775,996,000
805,589,000
822,067,000
836,633,000
887,400,000
928,523,000
964,109,000
1,016,507,000
1,046,803,000
1,091,662,000
1,091,662,0001,046,803,0001,016,507,000964,109,000928,523,000887,400,000836,633,000822,067,000805,589,000775,996,000719,061,000678,256,000615,976,000567,956,000519,889,000477,625,000541,401,000475,770,000444,814,000415,969,000000000000
       Property Plant Equipment 
19,972,000
19,062,000
19,592,000
19,506,000
19,300,000
19,711,000
19,437,000
20,410,000
20,704,000
21,332,000
33,618,000
33,457,000
33,106,000
33,152,000
32,572,000
31,901,000
33,209,000
33,946,000
35,190,000
37,265,000
37,602,000
37,951,000
38,657,000
34,397,000
36,713,000
37,510,000
37,112,000
37,182,000
39,728,000
39,728,00037,182,00037,112,00037,510,00036,713,00034,397,00038,657,00037,951,00037,602,00037,265,00035,190,00033,946,00033,209,00031,901,00032,572,00033,152,00033,106,00033,457,00033,618,00021,332,00020,704,00020,410,00019,437,00019,711,00019,300,00019,506,00019,592,00019,062,00019,972,000
       Goodwill 
23,823,000
25,736,000
25,669,000
25,838,000
25,794,000
25,045,000
25,319,000
25,319,000
25,319,000
26,118,000
26,181,000
26,723,000
30,482,000
29,345,000
29,314,000
29,296,000
30,927,000
30,125,000
28,307,000
28,054,000
28,091,000
27,481,000
27,432,000
19,359,000
19,638,000
19,357,000
19,435,000
19,434,000
19,434,000
19,434,00019,434,00019,435,00019,357,00019,638,00019,359,00027,432,00027,481,00028,091,00028,054,00028,307,00030,125,00030,927,00029,296,00029,314,00029,345,00030,482,00026,723,00026,181,00026,118,00025,319,00025,319,00025,319,00025,045,00025,794,00025,838,00025,669,00025,736,00023,823,000
       Long Term Investments 
150,343,000
143,284,000
155,733,000
176,120,000
209,666,000
224,241,000
264,420,000
299,242,000
304,770,000
342,327,000
359,381,000
390,364,000
452,712,000
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0000000000000000452,712,000390,364,000359,381,000342,327,000304,770,000299,242,000264,420,000224,241,000209,666,000176,120,000155,733,000143,284,000150,343,000
       Intangible Assets 
8,026,000
8,919,000
9,632,000
10,895,000
12,801,000
13,858,000
15,083,000
15,678,000
16,628,000
16,229,000
17,058,000
16,920,000
17,069,000
13,938,000
13,454,000
12,514,000
12,126,000
11,459,000
10,980,000
10,499,000
10,232,000
10,093,000
9,946,000
9,461,000
9,174,000
6,694,000
6,368,000
6,289,000
6,336,000
6,336,0006,289,0006,368,0006,694,0009,174,0009,461,0009,946,00010,093,00010,232,00010,499,00010,980,00011,459,00012,126,00012,514,00013,454,00013,938,00017,069,00016,920,00017,058,00016,229,00016,628,00015,678,00015,083,00013,858,00012,801,00010,895,0009,632,0008,919,0008,026,000
       Long-term Assets Other 
0
0
0
0
0
0
0
0
0
546,000
108,000
215,000
178,000
188,000
226,000
125,000
153,000
247,000
252,000
279,000
269,000
293,000
182,000
141,000
129,000
118,000
107,000
99,000
95,000
95,00099,000107,000118,000129,000141,000182,000293,000269,000279,000252,000247,000153,000125,000226,000188,000178,000215,000108,000546,000000000000
> Total Liabilities 
259,287,000
317,815,000
301,367,000
367,280,000
389,032,000
442,839,000
424,470,000
488,076,000
479,698,000
530,698,000
527,679,000
591,881,000
637,712,000
653,492,000
629,336,000
686,715,000
720,851,000
827,814,000
859,075,000
844,457,000
909,137,000
952,362,000
963,414,000
1,051,466,000
1,058,835,000
1,093,638,000
1,122,631,000
1,132,197,000
1,187,320,000
1,187,320,0001,132,197,0001,122,631,0001,093,638,0001,058,835,0001,051,466,000963,414,000952,362,000909,137,000844,457,000859,075,000827,814,000720,851,000686,715,000629,336,000653,492,000637,712,000591,881,000527,679,000530,698,000479,698,000488,076,000424,470,000442,839,000389,032,000367,280,000301,367,000317,815,000259,287,000
   > Total Current Liabilities 
149,871,000
162,552,000
143,043,000
153,643,000
172,551,000
175,961,000
155,600,000
189,208,000
188,129,000
228,267,000
214,308,000
226,616,000
232,249,000
271,184,000
237,339,000
295,057,000
319,337,000
374,625,000
353,445,000
329,640,000
328,932,000
356,413,000
344,781,000
404,373,000
400,530,000
418,422,000
391,401,000
397,462,000
442,969,000
442,969,000397,462,000391,401,000418,422,000400,530,000404,373,000344,781,000356,413,000328,932,000329,640,000353,445,000374,625,000319,337,000295,057,000237,339,000271,184,000232,249,000226,616,000214,308,000228,267,000188,129,000189,208,000155,600,000175,961,000172,551,000153,643,000143,043,000162,552,000149,871,000
       Short-term Debt 
135,970,000
173,119,000
176,018,000
226,434,000
221,959,000
21,339,000
259,937,000
0
0
59,912,000
63,571,000
53,309,000
50,466,000
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
000000000000000050,466,00053,309,00063,571,00059,912,00000259,937,00021,339,000221,959,000226,434,000176,018,000173,119,000135,970,000
       Short Long Term Debt 
135,970,000
173,119,000
176,018,000
226,434,000
221,959,000
21,339,000
259,937,000
0
0
59,912,000
63,571,000
53,309,000
50,466,000
57,715,000
55,218,000
101,131,000
108,490,000
132,655,000
138,497,000
109,063,000
106,668,000
102,629,000
101,703,000
150,726,000
151,881,000
143,411,000
141,003,000
132,386,000
179,241,000
179,241,000132,386,000141,003,000143,411,000151,881,000150,726,000101,703,000102,629,000106,668,000109,063,000138,497,000132,655,000108,490,000101,131,00055,218,00057,715,00050,466,00053,309,00063,571,00059,912,00000259,937,00021,339,000221,959,000226,434,000176,018,000173,119,000135,970,000
       Accounts payable 
93,396,000
107,470,000
87,916,000
96,278,000
121,482,000
124,401,000
115,027,000
128,220,000
138,319,000
153,552,000
137,174,000
157,557,000
158,996,000
174,140,000
164,351,000
166,973,000
180,521,000
205,198,000
192,118,000
188,914,000
193,657,000
212,807,000
195,821,000
207,611,000
206,722,000
218,555,000
205,621,000
212,230,000
212,376,000
212,376,000212,230,000205,621,000218,555,000206,722,000207,611,000195,821,000212,807,000193,657,000188,914,000192,118,000205,198,000180,521,000166,973,000164,351,000174,140,000158,996,000157,557,000137,174,000153,552,000138,319,000128,220,000115,027,000124,401,000121,482,00096,278,00087,916,000107,470,00093,396,000
       Other Current Liabilities 
10,575,000
12,572,000
13,511,000
16,785,000
13,017,000
13,236,000
11,288,000
14,069,000
9,953,000
8,928,000
8,561,000
7,769,000
22,787,000
37,705,000
17,770,000
26,953,000
30,326,000
35,380,000
22,830,000
31,663,000
28,607,000
39,749,000
47,257,000
46,036,000
41,927,000
55,420,000
44,777,000
18,787,000
17,885,000
17,885,00018,787,00044,777,00055,420,00041,927,00046,036,00047,257,00039,749,00028,607,00031,663,00022,830,00035,380,00030,326,00026,953,00017,770,00037,705,00022,787,0007,769,0008,561,0008,928,0009,953,00014,069,00011,288,00013,236,00013,017,00016,785,00013,511,00012,572,00010,575,000
   > Long-term Liabilities 
0
0
0
0
0
0
0
0
0
302,431,000
313,371,000
365,265,000
405,463,000
382,308,000
391,218,000
391,658,000
401,514,000
453,103,000
505,564,000
514,817,000
580,205,000
595,949,000
618,633,000
647,093,000
658,305,000
675,216,000
731,230,000
734,735,000
744,351,000
744,351,000734,735,000731,230,000675,216,000658,305,000647,093,000618,633,000595,949,000580,205,000514,817,000505,564,000453,103,000401,514,000391,658,000391,218,000382,308,000405,463,000365,265,000313,371,000302,431,000000000000
       Long-term Liabilities Other 
0
0
0
0
0
0
0
0
0
9,313,000
11,444,000
12,590,000
14,254,000
14,432,000
15,925,000
16,219,000
16,527,000
15,329,000
16,798,000
18,818,000
19,092,000
18,902,000
19,766,000
19,683,000
20,366,000
19,649,000
19,701,000
20,921,000
22,981,000
22,981,00020,921,00019,701,00019,649,00020,366,00019,683,00019,766,00018,902,00019,092,00018,818,00016,798,00015,329,00016,527,00016,219,00015,925,00014,432,00014,254,00012,590,00011,444,0009,313,000000000000
> Total Stockholder Equity
177,263,000
180,459,000
188,279,000
198,380,000
214,134,000
222,375,000
237,460,000
249,446,000
235,833,000
257,291,000
271,310,000
291,354,000
329,767,000
285,746,000
308,672,000
332,424,000
353,995,000
393,444,000
410,194,000
434,626,000
442,368,000
467,392,000
480,621,000
525,438,000
534,670,000
571,009,000
622,943,000
662,499,000
682,747,000
682,747,000662,499,000622,943,000571,009,000534,670,000525,438,000480,621,000467,392,000442,368,000434,626,000410,194,000393,444,000353,995,000332,424,000308,672,000285,746,000329,767,000291,354,000271,310,000257,291,000235,833,000249,446,000237,460,000222,375,000214,134,000198,380,000188,279,000180,459,000177,263,000
   Common Stock
54,259,000
54,259,000
54,259,000
54,259,000
54,259,000
54,259,000
54,259,000
54,259,000
54,259,000
54,259,000
54,259,000
54,259,000
54,259,000
54,259,000
54,259,000
54,259,000
54,259,000
54,259,000
54,259,000
54,259,000
54,259,000
54,259,000
54,259,000
54,259,000
54,259,000
0
54,259,000
0
0
0054,259,000054,259,00054,259,00054,259,00054,259,00054,259,00054,259,00054,259,00054,259,00054,259,00054,259,00054,259,00054,259,00054,259,00054,259,00054,259,00054,259,00054,259,00054,259,00054,259,00054,259,00054,259,00054,259,00054,259,00054,259,00054,259,000
   Retained Earnings 
88,078,000
92,522,000
99,085,000
103,776,000
109,927,000
121,089,000
183,310,000
194,774,000
181,240,000
206,181,000
220,451,000
237,735,000
276,163,000
232,559,000
257,527,000
282,035,000
303,370,000
342,591,000
368,697,000
395,102,000
389,972,000
417,824,000
434,644,000
471,651,000
482,041,000
520,879,000
584,180,000
625,225,000
650,036,000
650,036,000625,225,000584,180,000520,879,000482,041,000471,651,000434,644,000417,824,000389,972,000395,102,000368,697,000342,591,000303,370,000282,035,000257,527,000232,559,000276,163,000237,735,000220,451,000206,181,000181,240,000194,774,000183,310,000121,089,000109,927,000103,776,00099,085,00092,522,00088,078,000
   Capital Surplus 00000000000000000000000000000
   Treasury Stock00000000000000000000000000000
   Other Stockholders Equity 
28,734,000
30,420,000
31,878,000
37,673,000
47,204,000
45,996,000
-222,000
-110,000
-163,000
-194,000
-319,000
-320,000
-193,000
-419,000
-624,000
-734,000
-714,000
-413,000
-415,000
-17,000
133,000
208,000
1,574,000
2,067,000
1,268,000
0
2,499,000
0
0
002,499,00001,268,0002,067,0001,574,000208,000133,000-17,000-415,000-413,000-714,000-734,000-624,000-419,000-193,000-320,000-319,000-194,000-163,000-110,000-222,00045,996,00047,204,00037,673,00031,878,00030,420,00028,734,000



Balance Sheet

Currency in EUR. All numbers in thousands.




Cash Flow

Currency in EUR. All numbers in thousands.




Income Statement

Currency in EUR. All numbers in thousands.


Latest Income Statement (annual, 2023-03-31)

Gross Profit (+$)
totalRevenue643,984,000
Cost of Revenue-346,651,000
Gross Profit297,333,000297,333,000
 
Operating Income (+$)
Gross Profit297,333,000
Operating Expense-575,499,000
Operating Income68,485,000-278,166,000
 
Operating Expense (+$)
Research Development-
Selling General Administrative228,648,000
Selling And Marketing Expenses-
Operating Expense575,499,000228,648,000
 
Net Interest Income (+$)
Interest Income24,847,000
Interest Expense-10,574,000
Other Finance Cost-0
Net Interest Income14,273,000
 
Pretax Income (+$)
Operating Income68,485,000
Net Interest Income14,273,000
Other Non-Operating Income Expenses-
Income Before Tax (EBT)118,479,00068,485,000
EBIT - interestExpense = 59,813,000
91,345,000
101,919,000
Interest Expense10,574,000
Earnings Before Interest and Taxes (EBIT)70,387,000129,053,000
Earnings Before Interest and Taxes (EBITDA)145,306,000
 
After tax Income (+$)
Income Before Tax118,479,000
Tax Provision-23,482,000
Net Income From Continuing Ops94,997,00094,997,000
Net Income91,345,000
Net Income Applicable To Common Shares-
 
Non-recurring Events
Discontinued Operations-
Extraordinary Items-
Effect of Accounting Charges-
Other Items-
Non Recurring-
Other Operating Expenses1,702,000
Total Other Income/Expenses Net--14,273,000
 

Technical Analysis of Hikma Pharmaceuticals PLC
The psychology behind the price

Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.

General trend

First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of Hikma Pharmaceuticals PLC. The general trend of Hikma Pharmaceuticals PLC is UNKNOWN with 0.0% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine Hikma Pharmaceuticals PLC's overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.

Indicator phases

Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:

Indicator StateBullish trend Bearish trend
Overbought to neutralBullish pullback=Bearish reversal
Upper to lower neutralBullish correction=Bearish continuation
Nuetral to oversoldOversold=Oversold
Oversold to neutralBullish reversal=Bearish correction
Lower to upper neutralBullish continuation=Bearish pullback
Nuetral to overboughtOverbought=Overbought

1. Price Targets

1.1 Support & Resistance

Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.

Support is a price level at which demand for an asset is strong enough to prevent the price from falling further.
Resistance is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.


Score

Let's take a look at the Support & Resistance of Hikma Pharmaceuticals PLC.

The long score for the Support & Resistance is 0/1.
The longshort score for the Support & Resistance is 0/(-1 +1).

  • Between support/resistance: The price is trading between support and resistance lines.

The bullish price targets are: 173.00.

The bearish price targets are: 25.91.

Tweet this
Hikma Pharmaceuticals PLC Daily Support & Resistance Chart

2. Trend Indicators

2.1 Moving Averages

Shows the moving average of the selected period.

  • Moving averages are lagging trend indicators.
  • There are many types of moving averages.
  • Moving averages are also used within other indicators.

Score

Let's take a look at the Moving Averages of Hikma Pharmaceuticals PLC. The current mas is .

Directionalities and relatives.

Moving AverageAmount of candlesTrendPrice +/-vs. MA 50vs. MA 100vs. MA 200

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

Hikma Pharmaceuticals PLC Daily Moving Averages Chart
2.2 Moving Average Convergence/Divergence (MACD)

Shows the momentum of the selected period based on two moving averages.

  • MACD is a lagging momentum indicator.
  • Uses two moving averages.
  • Can show buy or sell signals based on momentum.
  • Can show overbought. and oversold. levels.

Score

Let's take a look at the Moving Average Convergence/Divergence (MACD) of Hikma Pharmaceuticals PLC.

Hikma Pharmaceuticals PLC Daily Moving Average Convergence/Divergence (MACD) ChartHikma Pharmaceuticals PLC Daily Moving Average Convergence/Divergence (MACD) Chart
2.3 Directional Movement Index (DMI)

The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index). The ADX helps you determine the strength of a trend.


Score

Let's take a look at the Directional Movement Index (DMI) of Hikma Pharmaceuticals PLC. The current adx is .

Hikma Pharmaceuticals PLC Daily Directional Movement Index (DMI) Chart
2.4 Parabolic SAR

Shows the current trend and potential entry and exit signals.

  • Parabolic SAR (stop and reverse) is a lagging trend indicator.
  • Shows the current trend.
  • Shows potential entry signals.
  • Shows  potential exit signals.
  • Can be used to place trailing stoplosses..

Score

Let's take a look at the Parabolic SAR of Hikma Pharmaceuticals PLC.

Hikma Pharmaceuticals PLC Daily Parabolic SAR Chart

3. Momentum Indicators

3.1 Relative Strength Index (RSI)

Measures the speed and change of price movements.

  • Leading momentum indicator, meaning the signals are instant.
  • Ranges between 0 and 100.
  • Above 70 is considered overbought.
  • Below 30 is considered oversold.
  • Above or below 50 can also be used to determine price trend or support and resistance.
  • RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
  • Can be used in many different ways

Score

Let's take a look at the Relative Strength Index (RSI) of Hikma Pharmaceuticals PLC.

Hikma Pharmaceuticals PLC Daily Relative Strength Index (RSI) ChartHikma Pharmaceuticals PLC Daily Relative Strength Index (RSI) Chart
3.2 Stochastic Oscillator

Compares a certain price to multiple prices ranging over time.

  • Leading momentum indicator, meaning the signals are instant.
  • Used to determine overbought and oversold areas much like the RSI.
  • Ranges between 0 and 100.
  • Above 80 is considered overbought.
  • Below 20 is considered oversold.
  • Consists of two lines named K and D.
  • K compares the highest high and lowest low on the selected price range.
  • The D line is a moving average of the K line.
  • Can be used to spot divergences

Score

Let's take a look at the Stochastic Oscillator of Hikma Pharmaceuticals PLC.

Hikma Pharmaceuticals PLC Daily Stochastic Oscillator ChartHikma Pharmaceuticals PLC Daily Stochastic Oscillator Chart
3.3 Commodity Channel Index (CCI)

Measures the difference between the current price and the historical average price.

  • Lagging or leading Momentum indicator
  • When the CCI is above zero, the price is above the historical average
  • When the CCI is below zero, the price is below the historical average
  • Used for spotting trends
    • If the CCI moves from negative or near zero to positive 100 that might indicate an uptrend
    • If the CCI moves from positive or near zero to negative -100 that might indicate a downtrend

Score

Let's take a look at the Commodity Channel Index (CCI) of Hikma Pharmaceuticals PLC.

Hikma Pharmaceuticals PLC Daily Commodity Channel Index (CCI) ChartHikma Pharmaceuticals PLC Daily Commodity Channel Index (CCI) Chart
3.4 Chande Momentum Oscillator (CMO)

Measures the difference between the sum of recent gains and the sum of recent losses. Then divides the result by the sum of all price movements in that period.

  • Lagging momentum indicator
  • Ranges between +100 and -100
  • Considered overbought above +50
  • Considered oversold below -50
  • It's possible to add a moving average that acts as a signal line

Score

Let's take a look at the Chande Momentum Oscillator (CMO) of Hikma Pharmaceuticals PLC.

Hikma Pharmaceuticals PLC Daily Chande Momentum Oscillator (CMO) ChartHikma Pharmaceuticals PLC Daily Chande Momentum Oscillator (CMO) Chart
3.5 Williams %R

 Shows the current price relative to the highest high over the last 14 days.
 

  • Lagging momentum indicator
  • Ranging between 0 and -100
  • Above -20 is considered overbought
  • Below -80 is considered oversold
  • Is prone to give false signals

Score

Let's take a look at the Williams %R of Hikma Pharmaceuticals PLC.

Hikma Pharmaceuticals PLC Daily Williams %R ChartHikma Pharmaceuticals PLC Daily Williams %R Chart

4. Volatility Indicators

4.1 Bollinger Bands

Shows if the price is to high or to low relative to an average.

  • Lagging volatility indicator
  • Uses 3 bands: one upper, one lower and one in the middle
  • Works best when the middle band reflects an intermediate trend (MA20).
  • When the price is moving closer to the upper band, the market might be overbought
  • When the price is moving closer to the lower band, the market might be oversold 

Score

Let's take a look at the Bollinger Bands of Hikma Pharmaceuticals PLC.

Hikma Pharmaceuticals PLC Daily Bollinger Bands Chart
4.2 Average True Range (ATR)
Measures market volatility
  • Leading volatility indicator
  • Can be used to determine stop-loss positions
  • Calculated by:
    • Current high minus the current low
    • Current high minus the previous close
    • Current low minus the previous close
  • The larger the range of the candles, the greater the ATR value

Score

Let's take a look at the Average True Range (ATR) of Hikma Pharmaceuticals PLC.

Hikma Pharmaceuticals PLC Daily Average True Range (ATR) ChartHikma Pharmaceuticals PLC Daily Average True Range (ATR) Chart

5. Volume Indicators

5.1 On-Balance Volume (OBV)

 Measures market volatility

  • Leading momentum indicator
  • Calculation:
    • If the closing price is above the previous closing price: OBV = previous OBV + current volume
    • If the closing price is below the previous closing price: OBV = previous OBV - current volume
    • If the closing price is the same as the previous closing price than the OBV is the same.
  • Can be used to confirm price trends
  • Can be used with divergences

Score

Let's take a look at the On-Balance Volume (OBV) of Hikma Pharmaceuticals PLC.

Hikma Pharmaceuticals PLC Daily On-Balance Volume (OBV) ChartHikma Pharmaceuticals PLC Daily On-Balance Volume (OBV) Chart
5.2 Money Flow Index (MFI)

Measures the flow of money in and out of a security

  • Lagging momentum indicator
  • Looks like RSI but uses volume as an extra metric (RSI only considers price)
  • Above 80 is considered overbought
  • Below 20 is considered oversold
  • Can be used with divergences

Score

Let's take a look at the Money Flow Index (MFI) of Hikma Pharmaceuticals PLC.

Hikma Pharmaceuticals PLC Daily Money Flow Index (MFI) ChartHikma Pharmaceuticals PLC Daily Money Flow Index (MFI) Chart

6. Summary

6.1. Notifications

TypeNotificationDate
PenkeCurrently no notifications for Hikma Pharmaceuticals PLC.

6.2. Trading Signals

Below you will find trading signals as the indicator is commonly used. This doesn't mean you should use it that way. Learn from these, but don't use them blindly. I recommend using at least 4 indicators, 1 from each category: trend, momentum, volatility and volume.

DateIndicatorSignal
2023-11-28 00:00:00CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2023-12-01 00:00:00STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-04 00:00:00STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2023-12-05 00:00:00STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-06 00:00:00STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2023-12-08 00:00:00STOCH LONG EXITThe %K line crosses below the %D line.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2023-12-11 00:00:00WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2023-12-12 00:00:00MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2023-12-15 00:00:00STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-18 00:00:00ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2023-12-20 00:00:00STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2023-12-21 00:00:00CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2023-12-22 00:00:00STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-27 00:00:00MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2023-12-28 00:00:00STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-01-02 00:00:00DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-01-03 00:00:00CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-01-04 00:00:00DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-01-08 00:00:00MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-09 00:00:00STOCH SHORT EXITThe %K line crosses above the %D line.
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-01-10 00:00:00STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-12 00:00:00STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-17 00:00:00RSI SHORT ENTRY LONG CLOSE70 crossover to downside
STOCH LONG EXITThe %K line crosses below the %D line.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2024-01-18 00:00:00ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-01-22 00:00:00MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-01-24 00:00:00STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-25 00:00:00STOCH SHORT EXITThe %K line crosses above the %D line.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-01-26 00:00:00STOCH LONG EXITThe %K line crosses below the %D line.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-01-30 00:00:00STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-01-31 00:00:00MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2024-02-01 00:00:00STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-06 00:00:00ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2024-02-07 00:00:00STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-02-08 00:00:00STOCH LONG EXITThe %K line crosses below the %D line.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-02-09 00:00:00SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-02-13 00:00:00STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2024-02-14 00:00:00DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-02-16 00:00:00STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-21 00:00:00DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
2024-02-22 00:00:00CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-02-23 00:00:00STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-02-26 00:00:00SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-02-27 00:00:00MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
2024-02-28 00:00:00CCI LONG ENTRY SHORT CLOSE100 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-03-01 00:00:00BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2024-03-04 00:00:00STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-06 00:00:00STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-08 00:00:00STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-11 00:00:00ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-03-12 00:00:00MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-03-13 00:00:00SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2024-03-14 00:00:00WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-03-15 00:00:00STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-18 00:00:00CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-03-19 00:00:00ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-03-20 00:00:00STOCH LONG EXITThe %K line crosses below the %D line.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-03-21 00:00:00STOCH SHORT EXITThe %K line crosses above the %D line.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-03-22 00:00:00SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-03-25 00:00:00DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-03-26 00:00:00SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2024-03-27 00:00:00SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-28 00:00:00DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
RSI LONG ENTRY SHORT CLOSE30 crossover to upside
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-04-02 00:00:00MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2024-04-03 00:00:00MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
STOCH LONG EXITThe %K line crosses below the %D line.
2024-04-10 00:00:00STOCH SHORT EXITThe %K line crosses above the %D line.
2024-04-15 00:00:00STOCH LONG EXITThe %K line crosses below the %D line.
2024-04-17 00:00:00DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-04-18 00:00:00WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside

6.3. Candlestick Patterns

Hikma Pharmaceuticals PLC Daily Candlestick Chart
DateCandlestick Pattern

6.4. Technical Score

Let's check the technical score of Hikma Pharmaceuticals PLC based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
OpenGreater thanClose148.000
Total0/1 (0.0%)
Penke

Good job! You gained 25 XP and 0   0   10 . What's next:

  • Share my analysis of Hikma Pharmaceuticals PLC with someone you think should read this too:
  • Are you bullish or bearish on Hikma Pharmaceuticals PLC? Let me know what you think in the comments.
  • Do you want an email if I find something interesting about Hikma Pharmaceuticals PLC? Add an email alert using the form below.
  • Join the community if you want to keep your earnings and track your progress: Join the community
  • Is this analysis useful to you? Support me via But Me a Coffee. I'll analyze the stock market faster for you!

Get notifications about Hikma Pharmaceuticals PLC

I send you an email if I find something interesting about Hikma Pharmaceuticals PLC.


Comments

How you think about this?

Leave a comment

Stay informed about Hikma Pharmaceuticals PLC.

Receive notifications about Hikma Pharmaceuticals PLC in your mailbox!